Australia's largest stock trading and investment forum Australia's #1 stock forum

morning traders 17 / 10, page-127

First 127 Last

Share
Profile

Follow
Goldwater

1,606 Posts.

235

17/10/18

11:13

Post #: 36153617
Share

Originally posted by Akki ↑

Originally posted by verce
https://trademarketresearch.com/143...growing-number-of-applications-in-the-market/

Duchenne Muscular Dystrophy Therapeutics Market is expected to witness high demand on account of the growing number of applications in the market

Market Segment by Manufacturers, this report covers:

Bristol-Myers Squibb (market cap 94 billion)
FibroGen (U.S.) (market cap 4.5 billion)
Italfarmaco (Italy)
Marathon
NS Pharma (U.S.)
PTC Therapeutics (U.S.) (market cap 1.9 billion)
Pfizer (market cap 260 billion)
ReveraGen BioPharma (U.S.)
Santhera Pharmaceuticals (Switzerland)
Sarepta Therapeutics (U.S.) (market cap 9.1 billion)

What's the market cap of little old ANP?!
Exactly and why do you think AEI & Platinum Asset Management took 25% of the company on the basis of 1102 going into the DMD trial.

Plus the fact Sarepta's ex Chairman taking it from $50M to $9B jumping on ANP's board to steer it.

Expand

This is exactly why ANP is going to get all the money flowing in from BIT now that it's run.

I'm accumulating right now before ANP has its next run. I think later today once the smart money starts to find out about ANP.
2 Upvote

Reply

Top Stories

IVR

Investigator Resources hits 8m @ 1.06% copper on-site Stuart Shelf JV project acreage

WC8

Leia pegmatite pulls up recoveries of 84% lithium for Wildcat in WA

Talking the US election, the spectre of Trump and what's hot on the ASX200: Wealth Within

BYH

Bryah gains $408K government rebate for work on copper target Narracoota

AI stocks: What to expect in 2024-25

There are more pages in this discussion • 147 more messages in this thread...

First 127 Last